Contributions
Abstract: EP1532
Type: ePoster
Abstract Category: Therapy - disease modifying - Tools for detecting therapeutic response
Background: Brain Volume Loss (BVL) is increasingly recognized as an intervenable imaging biomarker of disease worsening in Multiple Sclerosis (MS). It has been included in the recent iterations of NEDA-4 (No Evidence of Disease Activity). Clinical utility of BVL tools and BVL measurements has not been established.
Goal: We present the preliminary results of BraVo (for Brain Volume) pilot project, a collaborative multi-center project evaluating clinical usefulness of BVL measurements.
Methods: BraVo pilot project started in November 2014. Eleven MS Neurologists from 6 MS Clinics across Canada selected, from their practice, ten random subjects with at least 3 MRIs. Clinical information on disease course, treatment and relapse history were collected. Brain Volume changes are analyzed with segmentation-based Brain Parenchymal Fraction (BPF) or registration-based EdgeFlow, depending on MRI sequences used. Clinicians complete surveys to evaluate the usefulness of BVL in the management of their patients and the barriers to implement these tools in clinical practice.
Results: Clinical information from 63 subjects out of 110 is available. Women represent 78% of the cohort. The average age is 42 years old (range 22-64) and the average disease duration is 11 years (2-26 y). 90.5% are RRMS, as opposed to 9.5% of SPMS patients. EDSS is spanning from 0 to 7.5. 14% of patients are not taking a Disease Modifying Therapies (DMT), 72% were on a stable treatment for more than 2 years and 14% started a new treatment in the past 6 months. On average, these patients had 5.1 MRI over the observation period.
Conclusion: The BraVo pilot project will evaluate the clinical usefulness of Brain Volume tools. The population studied is varied, mainly RRMS patients under stable treatment regimen. As Brain Volume measurements in MS are emerging as a tool for DMT effectiveness in clinical practice, with NEDA-4, our project will appropriately evaluate the usefulness of BVL to monitor individualized patients under treatment.
Disclosure:
Philippe Beauchemin: Consulting fees: Novartis, EMD Serono.
Robert Carruthers: Grants/Research Support: Site PI for studies funded by MedImmune, Teva and Guthy Jackson; Speakers Bureau/Honoraria: Speaking fees for unbranded lectures from Biogen, Genzyme and Teva; Consulting Fees: Novartis, EMD Serono, Genzyme.
Roger Tam: nothing to disclose.
Andrew Riddehough: nothing to disclose.
David Li: has received research funding from the Canadian Institute of Health Research and Multiple Sclerosis Society of Canada. He is the Director of the UBC MS/MRI Research Group which has been contracted to perform central analysis of MRI scans for therapeutic trials with Novartis, Perceptives, Roche and Sanofi-Aventis. The UBC MS/MRI Research Group has also received grant support for investigator-initiated independent studies from Genzyme, Merck-Serono, Novartis and Roche. He has acted as a consultant to Vertex Pharmaceuticals and served on the Data and Safety Advisory Board for Opexa Therapeutics and Scientific Advisory Boards for Adelphi Group, Novartis and Roche. He has also given lectures which have been supported by non-restricted education grants from Novartis and Biogen.
Anthony Traboulsee: is a consultant for Novartis, Genzyme, Roche and a principal investigator on clinical trials with Biogen, Genzyme, Roche, and Chugai.
BraVo pilot project was funded by Novartis Canada Inc.
Abstract: EP1532
Type: ePoster
Abstract Category: Therapy - disease modifying - Tools for detecting therapeutic response
Background: Brain Volume Loss (BVL) is increasingly recognized as an intervenable imaging biomarker of disease worsening in Multiple Sclerosis (MS). It has been included in the recent iterations of NEDA-4 (No Evidence of Disease Activity). Clinical utility of BVL tools and BVL measurements has not been established.
Goal: We present the preliminary results of BraVo (for Brain Volume) pilot project, a collaborative multi-center project evaluating clinical usefulness of BVL measurements.
Methods: BraVo pilot project started in November 2014. Eleven MS Neurologists from 6 MS Clinics across Canada selected, from their practice, ten random subjects with at least 3 MRIs. Clinical information on disease course, treatment and relapse history were collected. Brain Volume changes are analyzed with segmentation-based Brain Parenchymal Fraction (BPF) or registration-based EdgeFlow, depending on MRI sequences used. Clinicians complete surveys to evaluate the usefulness of BVL in the management of their patients and the barriers to implement these tools in clinical practice.
Results: Clinical information from 63 subjects out of 110 is available. Women represent 78% of the cohort. The average age is 42 years old (range 22-64) and the average disease duration is 11 years (2-26 y). 90.5% are RRMS, as opposed to 9.5% of SPMS patients. EDSS is spanning from 0 to 7.5. 14% of patients are not taking a Disease Modifying Therapies (DMT), 72% were on a stable treatment for more than 2 years and 14% started a new treatment in the past 6 months. On average, these patients had 5.1 MRI over the observation period.
Conclusion: The BraVo pilot project will evaluate the clinical usefulness of Brain Volume tools. The population studied is varied, mainly RRMS patients under stable treatment regimen. As Brain Volume measurements in MS are emerging as a tool for DMT effectiveness in clinical practice, with NEDA-4, our project will appropriately evaluate the usefulness of BVL to monitor individualized patients under treatment.
Disclosure:
Philippe Beauchemin: Consulting fees: Novartis, EMD Serono.
Robert Carruthers: Grants/Research Support: Site PI for studies funded by MedImmune, Teva and Guthy Jackson; Speakers Bureau/Honoraria: Speaking fees for unbranded lectures from Biogen, Genzyme and Teva; Consulting Fees: Novartis, EMD Serono, Genzyme.
Roger Tam: nothing to disclose.
Andrew Riddehough: nothing to disclose.
David Li: has received research funding from the Canadian Institute of Health Research and Multiple Sclerosis Society of Canada. He is the Director of the UBC MS/MRI Research Group which has been contracted to perform central analysis of MRI scans for therapeutic trials with Novartis, Perceptives, Roche and Sanofi-Aventis. The UBC MS/MRI Research Group has also received grant support for investigator-initiated independent studies from Genzyme, Merck-Serono, Novartis and Roche. He has acted as a consultant to Vertex Pharmaceuticals and served on the Data and Safety Advisory Board for Opexa Therapeutics and Scientific Advisory Boards for Adelphi Group, Novartis and Roche. He has also given lectures which have been supported by non-restricted education grants from Novartis and Biogen.
Anthony Traboulsee: is a consultant for Novartis, Genzyme, Roche and a principal investigator on clinical trials with Biogen, Genzyme, Roche, and Chugai.
BraVo pilot project was funded by Novartis Canada Inc.